Pharma Industry

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Drugmaker Dr Reddy's Laboratories Ltd on Tuesday reported an 86 per cent dip in consolidated profit after tax at Rs 221.3 crore in the fourth quarter ended March 31, 2026 hit by lower generics sales in North America. The company had posted a profit after tax of Rs 1,586.7 crore in the corresponding quarter previous fiscal year, Dr Reddy's Laboratories Ltd said in a regulatory filing. Consolidated total revenue from operations in the fourth quarter stood at Rs 7,546.4 crore as against Rs 8,528.4 crore in the same period a year ago, it added. Revenue from generic drugs in North America in the quarter was down 51 per cent at Rs 1,756.2 crore as compared to Rs 3,558.6 crore in the year-ago period. On the other hand generics revenue in India grew 20 per cent at Rs 1,566.3 crore as compared to Rs 1,304.7 crore in the corresponding period a year ago, the company said. Similarly, generics revenue in Europe grew by 14 per cent to Rs 1,452 crore from Rs 1,275 crore in the year ago period.

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Govt urges pharma firms to cut import reliance, boost domestic production and diversify exports as data shows rising foreign value addition and heavy dependence on China and the US

The deal creates Apothecon Group, a specialty pharma company focused on regulated markets in the US, Europe and India, with plans to expand its pipeline, footprint and acquisitions

Indian pharma market's growth was led more by price increases that an uptick in consumption

Pharma firm acquires office units in Parinee I building as Mumbai office market sees rising absorption, lower vacancies, and steady growth in rentals

Indian pharmaceutical exports stood at nearly USD 29 billion up to February this financial year registering a growth of five per cent compared to the same period last year, a top official said on Saturday. K Raja Bhanu, Director General, Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) said the sector, currently valued at approximately USD 60 billion, is projected to grow to USD 130 billion by 2030. "Inspite of global challenges, pharmaceuticals exports have been one of the few sectors that has maintained its growth momentum. Pharmaceutical exports during the period AprilFebruary FY26 stood at USD 28.29 billion, reflecting a growth of 5.6 per cent compared to the same period in FY25 led by formulations, biologicals, vaccines and Ayush products," he said. The official further said the exports reached USD 30.47 billion in FY 202425, reflecting a growth of 9.4 percent year on year despite global pricing pressures and trade volatilities..

Duties for products made by certain larger companies will take effect in 120 days, while items from smaller manufacturers won't be hit for another 180 days, according to a White House statement

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

Pharmaceutical companies are increasingly turning to AI to accelerate R&D, betting on new modelling tools and automated labs to unlock efficiency gains across their pipeline

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

Uttar Pradesh is ramping up investments in pharma parks and medical device manufacturing to emerge as a major healthcare production hub in South Asia

Small pharma firms have flagged a steep surge in raw material and packaging costs amid global disruptions, warning of supply risks and seeking price controls

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.